vibostolimab

News

End of the line for MSD's TIGIT, LAG-3 cancer drugs

MSD has stopped development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline.

News

Person with their hand covering their face

More bad news for TIGIT as MSD stops another trial

Another TIGIT trial failure has been abandoned, casting a shadow once again over the target as a cancer immunotherapy strategy.

News

MSD has another TIGIT programme setback

A phase 3 trial of MSD’s anti-TIGIT antibody vibostolimab and PD-1 inhibitor pembrolizumab has been abandoned after a high rate of discontinuations rendered the study futi

End of the line for MSD's TIGIT, LAG-3 cancer drugs

More bad news for TIGIT as MSD stops another trial

MSD has another TIGIT programme setback

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks